AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26204351
Drug: Daily foetal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily foetal movement counting from 28 weeks' gestation (n = 100)
Trial: 23937186
Drug: Wise feedback
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wise feedback (treatment condition)
Trial: 15615822
Drug: Combined ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined ramipril at 5 mg/d and valsartan at 80 mg/d with increased furosemide dosage
Trial: 15615822
Drug: Valsartan at
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan at 160 mg/d
Trial: 15615822
Drug: Combined ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined ramipril at 5 mg/d and valsartan at 80 mg/d
Trial: 15615822
Drug: Ramipril at
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril at 10 mg/d
Trial: 9605723
Drug: Withholding treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding treatment (no AEDs)
Trial: 9605723
Drug: Subsequent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent treatment regimens after 3 failures
Trial: 9605723
Drug: Overall outcome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall outcome of epilepsy treatment
Trial: 2660559
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g sucralfate daily
Trial: 30132821
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg with glycopyrrolate 450 μg (first dose)
Trial: 30132821
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg with glycopyrrolate (second dose)
Trial: 30132821
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg with glycopyrrolate (first dose)
Trial: 30132821
Drug: Neostigmine 2.5
RxNorm normalized name: neostigmine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 2.5 mg with glycopyrrolate (first and second doses)
Trial: 28251295
Drug: Daily pin
RxNorm normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pin care (group A)
Trial: 28251295
Drug: Weekly pin
RxNorm normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pin care (group C)
Trial: 21165642
Drug: Nutrient ingestion
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient ingestion (24 g whey, 4.8 g leucine, 50 g maltodextrin)
Trial: 11544839
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of progestins and anticoagulants (500 mg, i.v., for 10 days for AH; 20 days for moderately- and poorly-differentiated cell CAC)
Trial: 11544839
Drug: Preoperative progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative progestin therapy without anticoagulants
Trial: 3006980
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg b.w. propranolol
Trial: 29057618
Drug: bococizumab 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bococizumab 0.25 mg/kg
Trial: 29037448
Drug: bococizumab 1
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bococizumab 1 mg/kg
Trial: 29037448
Drug: bococizumab 3
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bococizumab 3 mg/kg
Trial: 29037448
Drug: bococizumab 6
RxNorm normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bococizumab 6 mg/kg
Trial: 29057618
Drug: bococizumab 6
RxNorm normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bococizumab 6 mg/kg (all three doses)
Trial: 18314215
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg UDCA
Trial: 18314215
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg UDCA
Trial: 18314215
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg UDCA
Trial: 18314215
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of UDCA
Trial: 8410645
Drug: Experimental oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental oral intervention (taste, smell, and oral tactile stimulation)
Trial: 3102387
Drug: Single 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 800 mg dose of ofloxacin (32 patients)
Trial: 3102387
Drug: Single 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 400 mg dose of ofloxacin (55 patients)
Trial: 3102387
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a day dose of 600 mg ofloxacin (34 patients)
Trial: 3102387
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin twice a day for 7-10 days (19 patients with urinary tract infection)
Trial: 3102387
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin twice a day for 7-10 days (8 patients with enteric fever)
Trial: 25874951
Drug: Rebamipide 300
RxNorm normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide 300 mg three times daily for 8 weeks
Trial: 21407110
Drug: 1 ng/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ng/mL Escherichia coli lipopolysaccharide (LPS)
Trial: 21407110
Drug: 5 ng/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ng/mL Escherichia coli lipopolysaccharide (LPS)
Trial: 19216298
Drug: Topical skin
RxNorm normalized name: Betadine 7.5% Topical Skin Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical skin protectant lotion (IB1)
Trial: 15198188
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 7 days (288 patients)
Trial: 11844898
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg eletriptan
Trial: 11907491
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg almotriptan
Trial: 16190915
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg naratriptan
Trial: 11728541
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg eletriptan
Trial: 11728541
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg and 5 mg zolmitriptan
Trial: 19175613
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg eletriptan
Trial: 10233200
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rizatriptan
Trial: 9296454
Drug: Antioxidants (n‐acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (n‐acetylcysteine 150 mg/kg for 30 min then 20 mg/kg/h plus bolus doses of 1 g ascorbic acid and 400 mg alpha‐tocopherol)
Trial: 8420296
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pravastatin + Gemfibrozil)
Trial: 3749299
Drug: Caffeine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (20 to 160 mg)
Trial: 3749299
Drug: Caffeine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (160 mg)
Trial: 3749299
Drug: Caffeine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (various doses including 0, 20, 40, 80, 160 mg)
Trial: 19486913
Drug: Caffeine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (80 mg)
Trial: 31426272
Drug: SEDDS-CBD (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEDDS-CBD (25 mg)
Trial: 25439055
Drug: Pre-emptive early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive early interventions (PEI) including skill training for parents of younger children and courses in emotional well-being skills based on cognitive behavioural therapy for older children and youth.
Trial: 23311248
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and midazolam
Trial: 19220845
Drug: Straumann implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straumann implants
Trial: 15248876
Drug: Brånemark implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark implants
Trial: 18569900
Drug: Brief office
RxNorm normalized name: Office First Aid Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief office intervention (BOI) consisting of four weekly individual sessions lasting 10 to 40 minutes each, incorporating motivational interviewing and cognitive-behavioral techniques.
Trial: 12480588
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) in combination with radiotherapy
Trial: 28696503
Drug: Standard-dose P.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose P. pratense allergoid (6000 TU)
Trial: 28696503
Drug: High-dose P.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose P. pratense allergoid (18000 TU)
Trial: 25681064
Drug: SSM‐VIMT (malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSM‐VIMT (malaria transmission blocking vaccine)
Trial: 1932407
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine
Trial: 16423942
Drug: 1.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL/kg of iohexol over 35 sec (Group A)
Trial: 16423942
Drug: 1.7 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 mL/kg of iohexol over 35 sec (Group B)
Trial: 16423942
Drug: 2.5 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL/kg of iohexol over 35 sec (Group C)
Trial: 16423942
Drug: 1.7 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 mL/kg of iohexol over 25 sec (Group D)
Trial: 9737753
Drug: Fluid formulation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid formulation with 157 Na (270 mOsm x kg(-1))
Trial: 9737753
Drug: Fluid formulation
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid formulation with Performance (19.6 mEq x L(-1) Na, 380 mOsm)
Trial: 9737753
Drug: Fluid formulations
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid formulations with 19.6 Na or 19.6 Na + glucose
Trial: 8070505
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg controlled-release (CR) tablet bd
Trial: 8070505
Drug: Diltiazem 120
RxNorm normalized name: diltiazem 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120 mg controlled-release (CR) tablet bd
Trial: 8070505
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg immediate-release (IR) tablet tid
Trial: 2660558
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg three times a day and 400 mg at night
Trial: 2660558
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g four times a day orally for four weeks
Trial: 25119686
Drug: Pre-bronchodilator microspirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator microspirometry test (FEV1/FEV6 <0.73)
Trial: 22361399
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg intravenously)
Trial: 19927040
Drug: MenC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenC vaccine booster
Trial: 15616045
Drug: Isovolemic hemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolemic hemodilution (IH) performed with 500 mL; identical volume of hydroxyethyl starch administered.
Trial: 11788629
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GH (0.025 mg/kg per day)
Trial: 11788629
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose GH (0.05 mg/kg per day)
Trial: 11788629
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GH (0.1 mg/kg per day)
Trial: 10430551
Drug: ET (fentanyl)
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ET (fentanyl) with 200 microA direct current applied for 30 min at hourly intervals
Trial: 10430551
Drug: ET (fentanyl)
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ET (fentanyl) with 200 microA direct current applied for 30 min at 4-hourly intervals
Trial: 10430551
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 75 microg infused over 30 min every 4 h
Trial: 7560622
Drug: 12,500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12,500 IU of unfractionated heparin given subcutaneously twice daily for 4 months
Trial: 2245983
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg clotrimazole vaginal tablet (n = 33)
Trial: 7430504
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg prednisone (single dose)
Trial: 7430504
Drug: Three 50
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 50 mg prednisone doses given at 6-hr intervals
Trial: 6391933
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg fenclofenac per day
Trial: 6391933
Drug: Gold in
RxNorm normalized name: AVOBENZONE 20.36 mg in 1 mL / OCTISALATE 50.9 mg in 1 mL / OCTOCRYLENE 20.36 mg in 1 mL TOPICAL LOTION [Australian Gold Instant Bronzer 15 sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold in standard doses
Trial: 30912735
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (100 g, 72% cocoa)
Trial: 27068478
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered iron saccharate (200 mg, two applications)
Trial: 27068478
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered iron polymaltose complex (100 mg, twice a day for 8 weeks)
Trial: 27068478
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered iron saccharate
Trial: 27068478
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered iron polymaltose complex
Trial: 24846620
Drug: TelePain intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TelePain intervention (report of symptoms and receipt of a pain graph) weekly for 8 weeks
Trial: 22420597
Drug: quetiapine (25-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine (25-300 mg, flexibly dosed)
Trial: 15939920
Drug: Cisplatin 70
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 70 mg/qm(2) on day 1 and methotrexate 40 mg/qm(2) on days 8 and 15 of a 21-day cycle (CM)
Trial: 15939920
Drug: Methotrexate 30
RxNorm normalized name: METHOTREXATE 30MG/0.6ML AUTO INJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 30 mg/qm(2) on days 1, 15, and 22, vinblastine 3 mg/qm(2) on days 2, 15, and 22, epirubicin 45 mg/qm(2) on day 2, and cisplatin 70 mg/qm(2) on day 2 of a 28-day cycle (M-VEC)
Trial: 12424822
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of neuroleptic treatment
Trial: 10325444
Drug: Silymarin (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (420 mg/day) + Tacrine (40 mg/day for 6 weeks, then increased to 80 mg/day for 6 weeks)
Trial: 27829371
Drug: Consolidation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation therapy
Trial: 2955799
Drug: Orgotein (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orgotein (4 or 8 mg)
Trial: 23650901
Drug: Patch pump
RxNorm normalized name: subcut bolus insulin patch pump,200 unit,disposabl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch pump (PP)
Trial: 19781874
Drug: Related agents
RxNorm normalized name: HORMONES AND RELATED AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Related agents
Trial: 30123511
Drug: Early goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early goal-directed therapy (EGDT)
Trial: 18159013
Drug: Conventional empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional empirical therapy (Control)
Trial: 15321022
Drug: Grid laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grid laser photocoagulation and 0.5 mL of 40 mg/mL posterior subtenon triamcinolone
Trial: 12646340
Drug: pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 20 mg
Trial: 2330116
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of levodopa and carbidopa
Trial: 7408140
Drug: Dipyridamole (Persantine)
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole (Persantine) and aspirin
Trial: 20339615
Drug: DTPw-HepB-Hib fully
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw-HepB-Hib fully liquid vaccine
Trial: 20339615
Drug: DTPw and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPw and Hib vaccines administered separately
Trial: 1894496
Drug: Active PEMF
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PEMF therapy (pulsed electromagnetic fields)
Trial: 1894496
Drug: Inactive PEMF
RxNorm normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inactive PEMF therapy (control)
Trial: 6361788
Drug: Suprofen 400
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen 400 mg
Trial: 6361794
Drug: Diflunisal 750
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diflunisal 750 mg
Trial: 30569790
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg·kg‐1 of body mass)
Trial: 30569790
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg·kg‐1 of body mass of dextrose)
Trial: 22465901
Drug: Wellmune (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellmune (250 mg once daily)
Trial: 15912413
Drug: Tenoxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (20 mg)
Trial: 9895080
Drug: remifentanil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (all doses)
Trial: 7735336
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + Arginine (0.5 g/kg infused over 30 min)
Trial: 7735336
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + Pyridostigmine (120 mg orally at -60 min)
Trial: 3002577
Drug: Lumpectomy (L)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumpectomy (L)
Trial: 29150790
Drug: Yishen Qufeng
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yishen Qufeng Shengshi Recipe (YQSR), 200 mL, twice per day, orally for 6 months
Trial: 29150790
Drug: Losartan, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan, 50 mg/d orally for 6 months
Trial: 26506579
Drug: Family-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Treatment for Adolescent Bulimia Nervosa (FBT-BN)